Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia

Torres-Duque, Carlos A; Ocampo-Gómez, Jaime; Castillo, Mauricio Morales; Cano-Rosales, Diana; Giraldo-Montoya, Ãngela

dc.contributor.author	Torres-Duque, Carlos A
dc.contributor.author	Ocampo-Gómez, Jaime
dc.contributor.author	Castillo, Mauricio Morales
dc.contributor.author	Cano-Rosales, Diana
dc.contributor.author	Giraldo-Montoya, Ãngela
dc.date.accessioned	2025-02-03T20:21:54Z
dc.date.available	2025-02-03T20:21:54Z
dc.date.issued	2022-11
dc.identifier.citation	Torres-Duque, Carlos A et al. “Real-World Effectiveness of Omalizumab for Severe Allergic Asthma Treatment in Colombia.” BMC pulmonary medicine 22.1 (2022): 1–447	es_CO
dc.identifier.issn	1471-2466
dc.identifier.other	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142823496&doi=10.1186%2fs12890-022-02246-x&partnerID=40&md5=17cbf5074361b912d3858af685fc830a
dc.identifier.uri	http://hdl.handle.net/10818/63598
dc.description	10 páginas	es_CO
dc.description.abstract	El fenotipo alérgico es responsable de más del 50% de los casos de asma grave. En un enfoque gradual, se utilizan tratamientos complementarios como anti-IgE para el asma alérgica grave (AAG). Este estudio tuvo como objetivo describir la efectividad en el mundo real del omalizumab en pacientes adultos y pediátricos con AAG en Colombia.	es_CO
dc.format	application/pdf	es_CO
dc.language.iso	eng	es_CO
dc.publisher	BMC pulmonary medicine	es_CO
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject.other	Omalizumab
dc.subject.other	Asma alérgica
dc.title	Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia	es_CO
dc.type	journal article	es_CO
dc.type.hasVersion	publishedVersion	es_CO
dc.rights.accessRights	openAccess	es_CO
dc.identifier.eissn	10.1186/s12890-022-02246-x